Andere Kunden interessierten sich auch für
![Selective serotonin reuptake inhibitor discontinuation syndrome]( "Selective serotonin reuptake inhibitor discontinuation syndrome")
Selective serotonin reuptake inhibitor discontinuation syndrome29,99 €![Expression profile of the angiogenesis inhibitor vasohibin]( "Expression profile of the angiogenesis inhibitor vasohibin")
Expression profile of the angiogenesis inhibitor vasohibin32,99 €![Alternative oxidase]( "Alternative oxidase")
Alternative oxidase29,99 €![Oxidase Test]( "Oxidase Test")
Oxidase Test22,99 €![Reverse Transcriptase Inhibitor]( "Reverse Transcriptase Inhibitor")
Reverse Transcriptase Inhibitor25,99 €![Interaction of HIV Protease Inhibitor with Hepatic Drug Transporters]( "Interaction of HIV Protease Inhibitor with Hepatic Drug Transporters")
Interaction of HIV Protease Inhibitor with Hepatic Drug Transporters38,99 €![Epalrestat- An Aldose Reductase Inhibitor]( "Epalrestat- An Aldose Reductase Inhibitor")
Epalrestat- An Aldose Reductase Inhibitor32,99 €
Monoamine oxidase inhibitors (MAOIs) are a class of powerful antidepressant drugs prescribed for the treatment of depression. They are particularly effective in treating atypical depression, and have also shown efficacy in smoking cessation. Due to potentially lethal dietary and drug interactions, MAOIs had been reserved as a last line of defense, used only when other classes of antidepressant drugs (for example selective serotonin reuptake inhibitors and tricyclic antidepressants) have failed. Recently, however, a patch form of the drug selegiline, called Emsam, was developed. It was approved for use by the FDA on February 28, 2006. When applied transdermally the drug does not enter the gastro-intestinal system as it does when taken orally, thereby decreasing the dangers of dietary interactions associated with MAOI pills.